XML 53 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Taxes [Abstract]  
Schedule of Deferred Tax Assets and Liabilities Significant components of the Company’s deferred tax assets and liabilities at December 31, 2023 and 2022 are as follows:
(in thousands)  2023   2022 
Deferred tax assets:        
Net operating losses carry forward  $41,698   $44,233 
Deferred revenue   8,219    
-
 
Share-based compensation   1,512    1,334 
Research and development/orphan drug credits   20,509    17,247 
Capitalized research and development expenses   18,684    13,210 
Others   (57)   69 
Less: valuation allowance   (90,566)   (76,093)
Deferred tax assets, net  $
-
   $
-
 
Schedule of U.S. Federal Statutory Rates The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax losses for the year ended December 31, 2023 and 2022 are as follows:
(in thousands)  December 31,
2023
   December 31,
2022
 
                 
Federal statutory income taxes  $(10,252)   (21.0)%  $(6,943)   (21.0)%
State income taxes   (1,743)   (3.6)%   (4,863)   (14.7)%
Deferred true-up   176    0.4%   89    0.3%
Research and development/orphan drug tax credit   (3,263)   (6.7)%   (2,711)   (8.2)%
Other   608    1.2%   934    2.8%
Change in valuation allowance   14,474    29.7%   13,494    40.8%
Provision for income tax  $
-
    
-
   $
-
    
-